Skip to main content

Table 4 Clinical and laboratory findings in patients with rheumatoid arthritis and different disease activity and controls

From: Impact of disease activity on impaired glucose metabolism in patients with rheumatoid arthritis

  RA pts with DAS28-ESR ≥ 5.1 (N = 46) RA pts with DAS28-ESR < 5.1 (N = 44) P valuea P valuea
Controls vs.
RA pts with DAS28-ESR ≥ 5.1 vs. < 5.1 RA pts with DAS28-ESR ≥ 5.1 RA pts with DAS28-ESR < 5.1
Age (years) 52.8 ± 10.7 52.1 ± 9.2 ns ns ns
BMI (kg/m2) 25.6 ± 4.7 25.7 ± 3.8 ns ns ns
Female, n (%) 40/46 (87.0) 38/44 (86.4) ns ns ns
Hypertension, n (%) 12/46 (26.1) 16/44 (36.4) ns ns ns
WC (cm) 87.4 ± 12.9 86.4 ± 11.8 ns ns ns
Waist-to-hip ratio 0.85 ± 0.08 0.83 ± 0.08 ns ns ns
MetS, n (%) 12/46 (26.1) 7/44 (15.9) ns ns ns
ESR (mm/h) 40 (31–62) 14 (10–29) 0.000 0.000 ns
CRP (mg/l) 12 (5.4–20) 3.1 (1.5–5.3) 0.000 0.000 ns
IL-6 (pg/ml) 12.8 (4.4–24) 3.2 (2.0–11) 0.003 0.000 0.005
Glycemia (mmol/l) 4.97 ± 0.6 4.63 ± 0.6 0.046 ns ns
Insulin (pmol/l) 79 (58–120) 57 (39–91) 0.004 0.000 ns
C-peptide (pmol/l) 960 (680–1130) 700 (465–860) 0.011 0.003 ns
HOMA2-IR 1.7 (1.2–2.5) 1.3 (0.9–1.9) 0.003 0.000 ns
HOMA2-IR > 1 (%) 39/46 (84.0) 28/44 (63.6) 0.021 0.002 ns
HOMA2-%B 150 (118–195) 143 (115–184) ns ns ns
HOMA2-%S 61 (40–85) 81 (54–123) 0.004 0.000 ns
DAS28-ESR 6.08 ± 0.79 3.51 ± 0.85 0.000b   
RA duration (years) 8.5 (4–13) 10 (5–13) nsb   
GC therapy, n (%) 30/46 (65.2) 29/44 (65.9) nsb   
GC doses (mg/day) 6.2 (5.0–10) 5 (5–10) nsb   
GC therapy (years) 3.3 (2.0–6.0) 5 (3–6) nsb   
  1. Data are presented as mean values ± SD and as the median and interquartile range (IQR) or percentages. Two-tailed level of P < 0.05 was considered statistically significant and marked in bold
  2. Abbreviations: CRP C-reactive protein, DAS28 disease activity score of 28 joints, ESR erythrocyte sedimentation rate, GC glucocorticoids, HAQ Health Assessment Questionnaire, IL interleukin, MetS metabolic syndrome, MMP3 matrix metalloproteinase-3, VAS visual analogue scale (0–100 mm), WC waist circumference
  3. aP value for the intergroup difference was tested by ANOVA, Kruskal-Wallis, and Mann-Whitney or χ2 test with the Bonferroni post hoc test. bP value inside the RA group. Differences in mDAS28-SE, disease duration, and GC therapy were tested by Mann-Whitney tests